Published in Immunol Rev on December 01, 2006
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Human natural killer cells. Blood (2008) 7.37
Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 1.80
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69
Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med (2013) 1.53
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest (2014) 1.45
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood (2012) 1.43
T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J Immunol (2008) 1.32
Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res (2011) 1.31
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest (2014) 1.12
TGF-beta and tumors--an ill-fated alliance. Curr Opin Immunol (2008) 1.08
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol (2014) 1.04
CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest (2008) 1.01
Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence (2012) 1.01
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer (2010) 0.98
Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics (Sao Paulo) (2012) 0.98
Biomarkers in diabetic retinopathy and the therapeutic implications. Mediators Inflamm (2013) 0.97
Manifestations of immune tolerance in the human female reproductive tract. Front Immunol (2013) 0.94
Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma. Cancer Microenviron (2012) 0.94
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol (2015) 0.93
Pluripotent stem cell-derived natural killer cells for cancer therapy. Transl Res (2010) 0.93
The four types of Tregs in malignant lymphomas. J Hematol Oncol (2011) 0.93
Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy (2013) 0.92
Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. Sci Rep (2013) 0.89
The role of inflammation in the pathology of preeclampsia. Clin Sci (Lond) (2016) 0.87
Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front Immunol (2012) 0.87
T cell regulation of natural killer cells. J Exp Med (2013) 0.87
Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbeta. PLoS One (2010) 0.87
Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitis. J Neuroimmunol (2010) 0.87
Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells. J Immunol (2014) 0.86
NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol (2015) 0.85
Divergent contributions of regulatory T cells to the pathogenesis of chronic hepatitis C. Hum Vaccin Immunother (2013) 0.84
Immunology of hepatocellular carcinoma. World J Hepatol (2015) 0.83
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? J Immunol Res (2016) 0.81
NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival. J Immunol (2014) 0.81
Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery. Mol Ther (2010) 0.81
Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. Bone Marrow Res (2011) 0.80
Regulatory T cells and pulmonary hypertension. Trends Cardiovasc Med (2011) 0.79
Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol (2014) 0.79
A pilot study on acute inflammation and cancer: a new balance between IFN-gamma and TGF-beta in melanoma. J Exp Clin Cancer Res (2009) 0.79
Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation. Eur J Nucl Med Mol Imaging (2012) 0.78
Immunological tolerance and tumor rejection in embryo-aggregated chimeric mice - lessons for tumor immunity. BMC Cancer (2008) 0.78
Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes. Immunotherapy (2013) 0.78
Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. Oncoimmunology (2015) 0.76
Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cells. Neural Regen Res (2012) 0.76
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncoimmunology (2016) 0.75
Regulatory T Cells in Hepatitis B and C Virus Infections. Immune Netw (2016) 0.75
Perforin expression in peripheral blood lymphatic cells of patients subjected to laparoscopic or open cholecystectomy. Mediators Inflamm (2009) 0.75
Depletion of T regulatory cells promotes natural killer cell-mediated cardiac allograft vasculopathy. Transplantation (2014) 0.75
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Front Immunol (2017) 0.75
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70
The IKK complex contributes to the induction of autophagy. EMBO J (2009) 2.41
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol (2004) 2.13
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Apoptosis regulation in tetraploid cancer cells. EMBO J (2006) 1.89
Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol (2008) 1.89
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood (2004) 1.88
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol (2004) 1.86
Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009) 1.83
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res (2008) 1.82
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 1.80
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 1.76
Autophagy and cellular immune responses. Immunity (2013) 1.71
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One (2009) 1.70
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol (2011) 1.69
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res (2008) 1.69
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res (2009) 1.64
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 1.59
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis (2009) 1.56
Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev (2007) 1.55
The potential of exosomes in immunotherapy. Expert Opin Biol Ther (2005) 1.52
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol (2006) 1.52
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. Eur J Immunol (2005) 1.46
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1- invariant NKT cells to bacteria. J Immunol (2010) 1.44
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 1.43
Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res (2010) 1.43
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res (2007) 1.37
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Dendritic cell derived-exosomes: biology and clinical implementations. J Leukoc Biol (2006) 1.34
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 1.31
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J (2011) 1.28
Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med (2008) 1.23
Pyroptosis - a cell death modality of its kind? Eur J Immunol (2010) 1.23
Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol (2008) 1.22
Exosomes for immunotherapy of cancer. Adv Exp Med Biol (2003) 1.22
CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res (2013) 1.22
Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin Biol Ther (2005) 1.22
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res (2008) 1.21
Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology (2013) 1.21
Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J Immunother (2003) 1.20
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19
The immunogenicity of tumor cell death. Curr Opin Oncol (2009) 1.19
Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18
Harnessing γδ T cells in anticancer immunotherapy. Trends Immunol (2012) 1.17
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology (2012) 1.16
Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci (2010) 1.16
Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res (2012) 1.16
How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev (2011) 1.15
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res (2011) 1.14